Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2021
OIA documents prove PHARMAC's independent inquiry is a toothless whitewash
11 October 2021 - Following a damning survey of PHARMAC, National can also reveal documents received under OIA show the ...
Posted by Michael Wonder on 10 Oct 2021
PHARMAC negotiates deal for molnupiravir to treat COVID-19
11 October 2021 - PHARMAC has negotiated an agreement with supplier MSD to purchase the antiviral molnupiravir. ...
Posted by Michael Wonder on 10 Oct 2021
70 percent of Kiwis want Government to give PHARMAC more money - survey
10 October 2021 - New Zealanders have sent a clear message to the Government to fund medicines better or their ...
Posted by Michael Wonder on 06 Oct 2021
Where has PHARMAC gone?
7 October 2021 - As debate has intensified over the last year or so about the procurement of New Zealand’s ...
Posted by Michael Wonder on 30 Sep 2021
New Zealand Pharmaceutical Schedule - 1 October 2021
1 October 2021 - The October 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 21 Sep 2021
Covid-19 delta outbreak: major PHARMAC review report delayed by lockdown
22 September 2021 - Act says it is "not good enough" an interim report for a much touted independent PHARMAC ...
Posted by Michael Wonder on 16 Sep 2021
PHARMAC funds tocilizumab to treat cases of COVID-19
16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...
Posted by Michael Wonder on 16 Sep 2021
PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage
16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, ...
Posted by Michael Wonder on 14 Sep 2021
Limiting the impact on Kiwis as API leaves the NZ market
14 September 2021 - PHARMAC is working hard to limit the impact on over 1 million Kiwis who currently take ...
Posted by Michael Wonder on 06 Sep 2021
New Zealand’s tocilizumab supply to be paused
6 September 2021 - PHARMAC has today announced that Roche, the global pharmaceutical company which provides tocilizumab, will not provide New ...
Posted by Michael Wonder on 31 Aug 2021
New Zealand Pharmaceutical Schedule - 1 September 2021 update
1 September 2021 - The September 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...
Posted by Michael Wonder on 23 Aug 2021
Dulaglutide receives Medsafe approval
23 August 2021 - Dulaglutide will be funded from 1 September 2021. ...
Posted by Michael Wonder on 17 Aug 2021
Information Act shows racism in PHARMAC’s decision-making
17 August 2021 - Paati Māori Co-leader, Debbie Ngarewa-Packer, has received information that blatantly outlines the inequity within PHARMAC and ...
Posted by Michael Wonder on 17 Aug 2021
PHARMAC to fund new cardiovascular medicine with amended Special Authority criteria
17 August 2021 - Pharmac has approved funding for a new medicine with substantial health benefits for around 75,000 New ...